Clinical Analysis

The MRI Finding: Neurocysticercosis

MRI Stages of NCC

The Critical Question: CSF ADA of 19.58 U/L

What Elevated CSF ADA Means

CSF ADA Reference Values in Meningitis Studies

Interpreting the Full Clinical Picture

Two Diagnoses May Coexist — or NCC May Be a Red Herring

Key Clinical Reasoning

1. NCC alone does not elevate CSF ADA significantly — studies confirm CSF ADA in aseptic/parasitic meningitis is low (3–8 U/L range).
2. 13 kg weight loss in 6 months is a constitutional symptom far more typical of active tuberculosis (miliary or pulmonary TB) than of isolated NCC.
3. The combination of elevated CSF ADA + significant constitutional weight loss + headache should prompt aggressive TB workup even if MRI suggests NCC.
4. TB and NCC can co-exist in endemic populations (immunosuppression from TB increases susceptibility to CNS parasitosis, and both are endemic in similar geographic regions).

Recommended Workup

To Confirm/Exclude TBM

• CSF: CBNAAT/GeneXpert MTB/RIF Ultra (most sensitive), AFB smear & culture, cell count & differential (lymphocytic pleocytosis), protein, glucose
• CSF ADA >10 U/L supports TBM (this patient's value of 19.58 is significant)
• Serum LDH, CSF lactate
• CSF cytology (rule out lymphoma)

To Confirm NCC

• Serum ELISA (EITB) for anti-cysticercal antibodies — highly specific
• Check for extraneural cysts: fundoscopy (mandatory before antiparasitic therapy — to rule out ocular cysticercosis), subcutaneous nodules
• Stool examination for T. solium proglottids/eggs (in household contacts)

To Investigate Weight Loss

• Chest X-ray / CT chest — miliary TB, cavitary disease
• Sputum AFB × 3 / CBNAAT
• HIV serology (co-infection common, must be ruled out)
• IGRA (Quantiferon-TB Gold) or Mantoux test
• CBC (lymphopenia in TB, eosinophilia in parasitosis)
• Serum albumin (nutritional status)

Management Principles

If TBM is Confirmed (or High Suspicion)

• Intensive phase (2 months): HRZE (Isoniazid + Rifampicin + Pyrazinamide + Ethambutol)
• Continuation phase (7–10 months for TBM): HR
• Adjunctive dexamethasone (0.4 mg/kg/day tapering over 6–8 weeks) — reduces mortality and neurological sequelae
• Monitor for drug-induced hepatotoxicity (LFTs at baseline and 2 weeks)

For NCC (if confirmed active/viable cysts)

• Albendazole (15 mg/kg/day in 2 divided doses × 8–30 days) OR Praziquantel (50–100 mg/kg/day × 15–30 days)
• Concomitant corticosteroids (dexamethasone) to blunt inflammatory response from dying cysts — this overlap is favorable if TBM is being treated concurrently
• Anticonvulsants if seizures present
• Surgery for obstructive hydrocephalus or intraventricular cysts
• Caution: Anti-parasitic drugs are contraindicated before ruling out ocular cysticercosis (can cause retinal detachment)

⚠️ Important: If both TBM and NCC are present, dexamethasone/corticosteroids serve dual purposes (adjunctive in TBM + anti-inflammatory in NCC). However, anti-TB drugs should take priority; antiparasitic therapy can be introduced once TBM treatment is established.

Summary

Updated Clinical Re-Analysis

CSF Analysis — Detailed Interpretation

The CSF Glucose — Critical Reinterpretation

⚠️ This is an important insight: the CSF glucose of 144 is not evidence against meningitis — it reflects the patient's glycemic state. A simultaneous fasting blood glucose must be checked to calculate the CSF:blood glucose ratio.

Does This CSF Profile Fit TBM?

Does the Elevated CSF ADA (19.58 U/L) Still Matter?

• Fungal meningitis
• CNS sarcoidosis
• Autoimmune encephalitis (GFAP-astrocytopathy)
• Lymphoproliferative disease/CNS lymphoma
• Neurocysticercosis (inflammatory stage)

1. NCC itself — degenerating cysts trigger T-lymphocyte activation even with minimal pleocytosis in parenchymal disease
2. CNS lymphoma — must now move up the differential given 13 kg weight loss + elevated CSF protein + elevated ADA + acellular CSF
3. Carcinomatous meningitis — similar profile

The CSF Protein (168 mg/dL) — What It Tells Us

• Spinal block (Froin's syndrome)
• Guillain-Barré syndrome
• CNS lymphoma / leptomeningeal malignancy
• Chronic meningitis (e.g., fungal, NCC with basal involvement)
• Diabetic polyradiculopathy (relevant given the hyperglycemia)
• NCC (protein elevation in 40% of cases, even with normal cell counts)

Revised Differential Diagnosis

What Explains the 13 kg Weight Loss?

1. Intestinal taeniasis (T. solium adult tapeworm in gut) — NCC and intestinal tapeworm coexist in 10–15% of cases; tapeworm can cause malabsorption, anorexia, and weight loss
2. Undetected malignancy — must be excluded
3. HIV/immunocompromised state — predisposes to both NCC and opportunistic infections
4. Diabetes mellitus — the very high CSF glucose (144 mg/dL) and likely high serum glucose suggests possible uncontrolled DM, which causes weight loss
5. Occult systemic infection elsewhere

Immediate Next Steps

Mandatory

• Simultaneous serum glucose — to calculate CSF:blood ratio and confirm/exclude hyperglycemia as cause of high CSF glucose
• HIV serology (ELISA + confirmatory Western blot) — weight loss + NCC is a classic HIV presentation
• Serum anti-cysticercal antibodies (ELISA/EITB) — confirm NCC diagnosis
• Stool examination — proglottids/ova of T. solium (intestinal taeniasis co-existing)
• HbA1c + fasting glucose — assess for uncontrolled diabetes

To Rule Out Malignancy (Given 13 kg weight loss + acellular CSF + elevated protein)

• CSF cytology (ideally repeat with large volume, 10 mL) — to detect leptomeningeal malignancy
• Serum LDH, β2-microglobulin
• CT abdomen-pelvis — occult malignancy (lymphoma, GI tumor)
• CSF flow cytometry if lymphoma suspected

To Rule Out Fungal Meningitis

• CSF India ink stain
• CSF cryptococcal antigen (CrAg)
• CSF fungal culture

Management of Confirmed Parenchymal NCC

• Albendazole 15 mg/kg/day (max 800 mg/day) in 2 divided doses × 8–28 days — preferred over praziquantel (better CNS penetration, less interaction with dexamethasone)
• Dexamethasone 0.1 mg/kg/day × 2 weeks — to blunt the inflammatory response as cysts die (prevents seizures from peri-cystic edema)
• Anticonvulsants if seizures occur
• No antiparasitic therapy if only calcified cysts (dead cysts — no benefit)

Summary

Clinical Synthesis — HIV Negative

What Explains the 13 kg Weight Loss in a HIV-Negative NCC Patient?

1. Disseminated Cysticercosis (Most Important to Exclude)

• Myositis and progressive muscle wasting → weight loss
• Subcutaneous nodules (palpable)
• "Rice-grain" calcifications on plain X-ray of limbs/trunk

2. Uncontrolled Diabetes Mellitus

• Progressive weight loss (glucosuria, catabolic state)
• Increased susceptibility to parasitic infections
• Elevated CSF protein (diabetic polyradiculopathy/neuropathy)

3. Intestinal Taeniasis (Co-existing Tapeworm)

• Malabsorption
• Nausea, reduced appetite
• Gradual weight loss over months

4. Occult Malignancy (Must Still Be Excluded)

• CSF cytology — leptomeningeal carcinomatosis
• CT abdomen-pelvis — lymphoma, GI/pancreatic malignancy
• Serum LDH, CA-125, CEA, AFP, PSA (age/sex-appropriate markers)

Revised Diagnostic Picture

Immediate Priority Actions

Treatment Plan (Once DM and Malignancy Excluded)

If DM is confirmed: glycaemic control is essential before and during antiparasitic therapy — steroid use will worsen hyperglycaemia and requires close glucose monitoring.

If disseminated cysticercosis confirmed: treatment is the same but requires longer and potentially repeated cycles of albendazole under close monitoring, as mass die-off of cysts can provoke severe inflammatory reactions.

Bottom Line

Case Solved

HbA1c 8.9% | FBS 230 mg/dL | PPBS 320 mg/dL | Urine sugar 3+ | X-ray limbs — Normal

Final Unified Diagnosis

How DM Explains Everything in This Case

CSF Glucose Re-interpreted Definitively

The Complete Pathophysiological Story

Poorly controlled T2DM (HbA1c 8.9%)
        ↓
Impaired cell-mediated immunity (T-cell dysfunction in DM)
        ↓
Susceptibility to Taenia solium cysticercus CNS invasion
        ↓
Parenchymal NCC → headache, elevated CSF protein, elevated ADA
        ↓
Osmotic diuresis + glucosuria + catabolism
        ↓
13 kg weight loss over 6 months

Final Diagnosis Summary

Treatment Plan

1. Antiparasitic Therapy (NCC)

Albendazole is preferred over praziquantel: better CNS penetration, not affected by dexamethasone (praziquantel levels are reduced by corticosteroids and rifampicin).

2. Diabetes Management — Critical Priority

⚠️ Dexamethasone will worsen hyperglycaemia significantly. Blood glucose monitoring is mandatory 2–4 times daily during steroid co-administration.

3. Symptomatic

• Analgesics (paracetamol) for headache during cyst die-off inflammatory phase
• Anticonvulsants (levetiracetam or phenytoin) if seizures occur during treatment
• Seizure precautions — advise patient, restrict driving

4. Follow-up

Key Teaching Points from This Case

1. CSF glucose must always be interpreted against simultaneous serum glucose — never in isolation. A CSF glucose of 144 is meaningless without knowing the blood glucose.
2. Parenchymal NCC has normal CSF in 50% of cases — acellular CSF does not exclude NCC.
3. Elevated CSF ADA is not pathognomonic for TBM — it reflects T-cell activation from any cause, including NCC.
4. Uncontrolled DM is the single unifying diagnosis here — explains weight loss, high CSF glucose, impaired immunity predisposing to NCC, and elevated CSF protein.
5. Dexamethasone + antiparasitic therapy in a diabetic — steroid-induced hyperglycaemia is predictable and must be pre-emptively managed with insulin.

Dosing Calculations — Weight 64 kg

1. Albendazole

Albendazole absorption is significantly enhanced when taken with a fatty meal (e.g., milk, peanut butter) — increases bioavailability 5-fold. Counsel patient specifically.

2. Dexamethasone

3. Albendazole Pre-treatment Weight Note

Diabetes Management at 64 kg

Insulin (Required during Dexamethasone course)

• Add rapid-acting insulin (aspart/lispro) 4–6 units before main meals, titrated to PPBS
• PPBS target: <180 mg/dL during illness

Blood Glucose Monitoring Plan

⚠️ Dexamethasone particularly spikes post-lunch and afternoon glucose. Watch for afternoon hyperglycaemia even if fasting glucose appears controlled.

Complete Prescription Summary

Follow-up Schedule

Expected Outcome

• NCC cysts → collapse → calcify over 2–6 months on MRI
• Headache should resolve within 2–4 weeks
• Weight should recover once glycaemic control is achieved — weight loss in DM is reversible with treatment
• Target: regain 5–8 kg over next 3 months as glucose normalises